Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
12:45pm, Thursday, 06'th Oct 2022 Zacks Investment Research
CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.
Stock Market Rallies Powerfully Off Lows; Lamb Weston, Sarepta, AMN In Focus | Stock Market Today
03:52pm, Wednesday, 05'th Oct 2022
But it's too early to declare a market bottom. Stock Market Today: October 5, 2022 Hosts: Ali Coram & Ken Shreve Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: h
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
01:18pm, Wednesday, 05'th Oct 2022 Zacks Investment Research
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:15pm, Friday, 30'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2022
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate
05:20pm, Friday, 30'th Sep 2022 Zacks Investment Research
If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate
03:03pm, Friday, 30'th Sep 2022
If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
12:30pm, Thursday, 29'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has submitted a Bio
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
05:59pm, Wednesday, 28'th Sep 2022 Benzinga
PepGen Inc (NASDAQ: PEPG) reported data from PGN-EDO51's SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities.
SVB notes that PGN-EDO51's safety profile was g
$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying
12:35pm, Friday, 16'th Sep 2022 Benzinga
Although US stocks closed lower on Thursday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stoc
Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
11:00am, Wednesday, 14'th Sep 2022 GlobeNewswire Inc.
With current cash and projected revenue, offering is expected to fund operations to profitability With current cash and projected revenue, offering is expected to fund operations to profitability
Sarepta prices almost $1 billion convertible bond offering
07:10am, Wednesday, 14'th Sep 2022
Sarepta Therapeutics Inc. SRPT, -9.77% said Wednesday it has priced $980 million of convertible senior unsecured notes that mature in September of 2027. The company will reduce the potential dilution
Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027
08:41pm, Monday, 12'th Sep 2022 GlobeNewswire Inc.
– With current cash and projected revenue, offering is expected to fund operations to profitability
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
03:20pm, Monday, 12'th Sep 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
12:47pm, Monday, 12'th Sep 2022
Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
Arm Vs. Qualcomm In A Huge Lawsuit With Little Coverage, I Explain
07:15am, Monday, 12'th Sep 2022 Seeking Alpha
I had no idea that ARM was suing Qualcomm over IP infringement. See why if QCOM is successful in the laptop CPU market, it could easily add $100B in market cap.
